这也意味着，在"反内卷"的集采新原则下，中国药品采购机制正经历一场兼顾效率与临床需求 的深度改革。 记者丨季媛媛 编辑丨包芳鸣 药品集采进入第十一批， 政策规则正从"唯低价"向"质量优先"悄然转身， 一场兼顾效率与临 床需求的改革新试验正在展开。 8月6日，全国医疗机构正式启动第十一批国家组织药品集中采购需求量填报工作。根据国家医 保局披露的信息，本次集采共涉及55个品种，梳理报量工作特点不难看出，一方面，与以往不 同， 此次集采报量首次允许医疗机构按厂牌报量， 改变了以往只能按药品通用名报量的规 则；另一方面， 设置了80%的报量红线， 要求医疗机构报量不得低于两年平均用量的80%。 此外，对于存在临床需求明显减少、业务调整等因素导致预期用量显著减少的， 医疗机构可 作出书面说明后按实际需求报量。 此次报量工作也明确需要与基本药物、儿童用药等政策保 持衔接，对于基本药物规格，报量系统中专门作出标注，如该规格未通过质量和疗效一致性评 价，医疗机构可自行确定折算比例，并在报量时作出说明。对于儿童适宜品规，如未通过一致 性评价，医疗机构认为难以替代、报量无法折算的，可根据实际需要报量并作出说明。 国家医保局在填报 ...

Group 1 - Aikolan's controlling shareholder Liu Yi terminated the share transfer agreement for 4 million shares, which represents 5% of the company's total share capital, with no change in control [1] - Wancheng Group announced a cash dividend of 4.00 yuan per 10 shares, totaling 71.9959 million yuan, with the record date on May 19, 2025 [1] - Wanda Film plans to invest in Lezi Tiancheng and engage in strategic cooperation, acquiring a total of 7% equity in the company [2] Group 2 - China Resources Double Crane's subsidiaries received approval for two drugs, indicating progress in their product pipeline [3] - Fosun Pharma's subsidiary's drug was included in the breakthrough therapy program, highlighting its innovative potential [4] - Zhongheng Group's subsidiary received approval for naloxone injection, enhancing its product offerings [5] Group 3 - Shenzhen Airport reported a passenger throughput of 5.3202 million in April, a year-on-year increase of 23.50% [8] - Hangzhou Bank successfully issued 5 billion yuan in technology innovation bonds, aimed at supporting tech innovation [10] - Jiuzhou Pharmaceutical received approval for a raw material drug used in treating severe depression, expanding its product range [12] Group 4 - Aihua Group reported a 25.38% decline in revenue for the first four months of the year, indicating potential challenges [27] - Changhua Group received a project designation notice from a well-known new energy vehicle company, with an expected total sales amount of approximately 108 million yuan [28] - Nanchao Food reported a slight revenue decrease of 0.98% in April, reflecting market conditions [30]

Core Viewpoint - China Resources Double Crane Pharmaceutical (华润双鹤) announced that its wholly-owned subsidiary Anhui Double Crane Pharmaceutical Co., Ltd. and its holding subsidiary Double Crane Tianan Pharmaceutical (Guizhou) Co., Ltd. received approval from the National Medical Products Administration for the supplementary applications of two drugs: Dextrose Sodium Chloride Injection and Metformin Empagliflozin Tablets (I) [1] Group 1 - Dextrose Sodium Chloride Injection has passed the consistency evaluation of quality and efficacy for generic drugs, primarily used for cerebrovascular diseases. The total R&D investment for this drug as of the announcement date is 2.7253 million yuan, with an estimated domestic market sales of 658 million yuan in 2024 [1] - Metformin Empagliflozin Tablets (I) has received approval for a change in the marketing authorization holder, with the drug approval number remaining unchanged. The total R&D investment for this drug as of the announcement date is 5.1956 million yuan, with an estimated domestic market sales of approximately 340 million yuan in 2024 [1]

Core Viewpoint - China Resources Double Crane has announced that its subsidiaries have successfully passed the consistency evaluation for generic drugs and received approval for supplemental drug applications, enhancing the company's product line and market competitiveness [1] Group 1: Product Approvals - The wholly-owned subsidiary Anhui Double Crane's Dextrose Sodium Chloride Injection has passed the consistency evaluation, which is primarily used for treating increased intracranial pressure, with a global sales figure of $99.65 million [1] - The holding subsidiary Double Crane Tianan's Metformin and Empagliflozin Tablets (I) is indicated for type 2 diabetes patients, with global sales of $73.17 million [1] Group 2: Market Context - In the domestic market, there are 14 companies that have passed the consistency evaluation for Dextrose Sodium Chloride Injection, and 13 companies for Metformin and Empagliflozin Tablets (I) [1] - The approvals of these products are expected to enrich the product line of China Resources Double Crane and enhance its competitive position in the market [1]